TheStreet upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a d rating to a c- rating in a report published on Monday morning.

NTLA has been the subject of a number of other research reports. Oppenheimer restated a hold rating on shares of Intellia Therapeutics in a research report on Tuesday, December 12th. BidaskClub upgraded Intellia Therapeutics from a sell rating to a hold rating in a research report on Friday, December 29th. JMP Securities started coverage on Intellia Therapeutics in a research report on Thursday, March 8th. They issued an outperform rating for the company. Barclays raised their price target on Intellia Therapeutics from $33.00 to $46.00 and gave the company an overweight rating in a research report on Wednesday, March 7th. Finally, Wedbush restated an outperform rating and issued a $36.00 price target on shares of Intellia Therapeutics in a research report on Thursday, March 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $34.83.

How to Become a New Pot Stock Millionaire

Intellia Therapeutics stock opened at $23.77 on Monday. Intellia Therapeutics has a 52-week low of $11.15 and a 52-week high of $35.99. The firm has a market capitalization of $996.53, a price-to-earnings ratio of -12.78 and a beta of 2.42.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 31.27%. The firm had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $8.84 million. During the same quarter in the prior year, the business earned ($0.31) EPS. The company’s quarterly revenue was up 19.6% compared to the same quarter last year. analysts forecast that Intellia Therapeutics will post -2.27 earnings per share for the current fiscal year.

In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of Intellia Therapeutics stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $26.78, for a total transaction of $14,746,273.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth about $146,000. SG Americas Securities LLC increased its position in Intellia Therapeutics by 61.3% during the 3rd quarter. SG Americas Securities LLC now owns 10,169 shares of the company’s stock worth $253,000 after purchasing an additional 3,863 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Intellia Therapeutics during the 4th quarter worth about $230,000. The Manufacturers Life Insurance Company increased its position in Intellia Therapeutics by 451.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock worth $212,000 after purchasing an additional 10,825 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in Intellia Therapeutics by 109.7% during the 2nd quarter. New York State Common Retirement Fund now owns 15,100 shares of the company’s stock worth $242,000 after purchasing an additional 7,899 shares in the last quarter. Hedge funds and other institutional investors own 67.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/intellia-therapeutics-ntla-upgraded-to-c-by-thestreet/1952743.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.